Point-of-care diagnostic devices and chronic disease management
Sinocare manufactures POCT (point-of-care testing) devices—primarily blood glucose meters and test strips—serving chronic disease management across China and export markets. The tech stack reveals a dual-channel architecture: cloud-native backend (Spring Boot, Kubernetes, PostgreSQL, Kafka) paired with embedded systems (ARM Cortex-M0/M3/M4, C, Bluetooth), reflecting both connected diagnostics and sensor-grade hardware. Active projects in AI medical product development and digital warehouse transformation signal a shift from hardware-only to data-driven, software-enabled care platforms.
Sinocare Inc., founded in 2002 and publicly listed on the Shenzhen Stock Exchange (stock code 300298), designs and manufactures point-of-care diagnostic devices with a focus on glucose monitoring and chronic disease management. The company operates across R&D, manufacturing, and distribution, with products certified to ISO 13485 and EU CE standards. Core offerings include glucometer devices and test strips sold domestically and exported internationally. The organization spans 1,001–5,000 employees across engineering, sales, marketing, operations, and manufacturing functions, with active hiring concentrated in China.
Sinocare runs ARM-based embedded systems (Cortex-M0/M3/M4 microcontrollers, C, Bluetooth) for sensor hardware, paired with a cloud backend using Spring Boot, Kubernetes, PostgreSQL, Kafka, and RocketMQ for data integration and diagnostics platforms.
Active projects include AI medical product development, digital warehouse transformation, new product launches, workshop digitalization, and advanced fixture technology research—indicating expansion beyond traditional POCT hardware into software platforms and manufacturing automation.
Other companies in the same industry, closest in size